325 related articles for article (PubMed ID: 32699213)
1. Ubiquitination and deubiquitination of MCL1 in cancer: deciphering chemoresistance mechanisms and providing potential therapeutic options.
Wu X; Luo Q; Liu Z
Cell Death Dis; 2020 Jul; 11(7):556. PubMed ID: 32699213
[TBL] [Abstract][Full Text] [Related]
2. The deubiquitinating enzyme USP20 regulates the stability of the MCL1 protein.
Feng J; Liu P; Li X; Zhang D; Lin H; Hou Z; Guo C; Niu Y; Dai B; Wang O; Qi M; Wang H; Zhou H
Biochem Biophys Res Commun; 2022 Feb; 593():122-128. PubMed ID: 35063767
[TBL] [Abstract][Full Text] [Related]
3. From Inhibition to Degradation: Targeting the Antiapoptotic Protein Myeloid Cell Leukemia 1 (MCL1).
Papatzimas JW; Gorobets E; Maity R; Muniyat MI; MacCallum JL; Neri P; Bahlis NJ; Derksen DJ
J Med Chem; 2019 Jun; 62(11):5522-5540. PubMed ID: 31117518
[TBL] [Abstract][Full Text] [Related]
4. Interplay between protein acetylation and ubiquitination controls MCL1 protein stability.
Shimizu K; Gi M; Suzuki S; North BJ; Watahiki A; Fukumoto S; Asara JM; Tokunaga F; Wei W; Inuzuka H
Cell Rep; 2021 Nov; 37(6):109988. PubMed ID: 34758305
[TBL] [Abstract][Full Text] [Related]
5. Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors.
Zhang S; Zhang M; Jing Y; Yin X; Ma P; Zhang Z; Wang X; Di W; Zhuang G
Nat Commun; 2018 Jan; 9(1):215. PubMed ID: 29335437
[TBL] [Abstract][Full Text] [Related]
6. MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation.
Arai S; Varkaris A; Nouri M; Chen S; Xie L; Balk SP
Elife; 2020 Jun; 9():. PubMed ID: 32484436
[TBL] [Abstract][Full Text] [Related]
7. SUMOylation of MCL1 protein enhances its stability by regulating the ubiquitin-proteasome pathway.
Li S; Wang J; Hu G; Aman S; Li B; Li Y; Xia K; Yang Y; Ahmad B; Wang M; Wu H
Cell Signal; 2020 Sep; 73():109686. PubMed ID: 32504673
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis.
Arai S; Jonas O; Whitman MA; Corey E; Balk SP; Chen S
Clin Cancer Res; 2018 Nov; 24(21):5458-5470. PubMed ID: 30021909
[No Abstract] [Full Text] [Related]
9. MARCH5 requires MTCH2 to coordinate proteasomal turnover of the MCL1:NOXA complex.
Djajawi TM; Liu L; Gong JN; Huang AS; Luo MJ; Xu Z; Okamoto T; Call MJ; Huang DCS; van Delft MF
Cell Death Differ; 2020 Aug; 27(8):2484-2499. PubMed ID: 32094511
[TBL] [Abstract][Full Text] [Related]
10. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
Gasca J; Flores ML; Giráldez S; Ruiz-Borrego M; Tortolero M; Romero F; Japón MA; Sáez C
Oncotarget; 2016 Aug; 7(33):52751-52765. PubMed ID: 27409838
[TBL] [Abstract][Full Text] [Related]
11. ALG-2 couples T cell activation and apoptosis by regulating proteasome activity and influencing MCL1 stability.
He TS; Ji W; Zhang J; Lu J; Liu X
Cell Death Dis; 2020 Jan; 11(1):5. PubMed ID: 31919392
[TBL] [Abstract][Full Text] [Related]
12. Chaperone-mediated autophagy promotes lung cancer cell survival through selective stabilization of the pro-survival protein, MCL1.
Suzuki J; Nakajima W; Suzuki H; Asano Y; Tanaka N
Biochem Biophys Res Commun; 2017 Jan; 482(4):1334-1340. PubMed ID: 27939888
[TBL] [Abstract][Full Text] [Related]
13. HUWE1 controls MCL1 stability to unleash AMBRA1-induced mitophagy.
Strappazzon F; Di Rita A; Peschiaroli A; Leoncini PP; Locatelli F; Melino G; Cecconi F
Cell Death Differ; 2020 Apr; 27(4):1155-1168. PubMed ID: 31434979
[TBL] [Abstract][Full Text] [Related]
14. MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma.
Fu D; Pfannenstiel L; Demelash A; Phoon YP; Mayell C; Cabrera C; Liu C; Zhao J; Dermawan J; Patil D; DeVecchio J; Kalady M; Souers AJ; Phillips DC; Li X; Gastman B
Cell Death Dis; 2022 Jan; 13(1):63. PubMed ID: 35042842
[TBL] [Abstract][Full Text] [Related]
15. Proteasomal degradation of the tumour suppressor FBW7 requires branched ubiquitylation by TRIP12.
Khan OM; Almagro J; Nelson JK; Horswell S; Encheva V; Keyan KS; Clurman BE; Snijders AP; Behrens A
Nat Commun; 2021 Apr; 12(1):2043. PubMed ID: 33824312
[TBL] [Abstract][Full Text] [Related]
16. GSK3B-mediated phosphorylation of MCL1 regulates axonal autophagy to promote Wallerian degeneration.
Wakatsuki S; Tokunaga S; Shibata M; Araki T
J Cell Biol; 2017 Feb; 216(2):477-493. PubMed ID: 28053206
[TBL] [Abstract][Full Text] [Related]
17. The role of post-translational modifications in the regulation of MCL1.
Li S; Guo W; Wu H
Cell Signal; 2021 May; 81():109933. PubMed ID: 33508399
[TBL] [Abstract][Full Text] [Related]
18. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
Teh TC; Nguyen NY; Moujalled DM; Segal D; Pomilio G; Rijal S; Jabbour A; Cummins K; Lackovic K; Blombery P; Thompson E; Ekert PG; Lessene G; Glaser SP; Huang DCS; Roberts AW; Guthridge MA; Wei AH
Leukemia; 2018 Feb; 32(2):303-312. PubMed ID: 28751770
[TBL] [Abstract][Full Text] [Related]
19. TRIM17 and TRIM28 antagonistically regulate the ubiquitination and anti-apoptotic activity of BCL2A1.
Lionnard L; Duc P; Brennan MS; Kueh AJ; Pal M; Guardia F; Mojsa B; Damiano MA; Mora S; Lassot I; Ravichandran R; Cochet C; Aouacheria A; Potts PR; Herold MJ; Desagher S; Kucharczak J
Cell Death Differ; 2019 May; 26(5):902-917. PubMed ID: 30042493
[TBL] [Abstract][Full Text] [Related]
20. Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells.
Inoue C; Sobue S; Kawamoto Y; Nishizawa Y; Ichihara M; Abe A; Hayakawa F; Suzuki M; Nozawa Y; Murate T
Biochem Biophys Res Commun; 2020 May; 525(4):1074-1080. PubMed ID: 32184020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
